Printer Friendly

FDA ADVISORY PANEL TO CONSIDER MEDTRONIC PCD DEVICE AT FEBRUARY MEETING

FDA ADVISORY PANEL TO CONSIDER MEDTRONIC PCD DEVICE AT FEBRUARY MEETING
 MINNEAPOLIS, Jan. 8 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT), said today that the company had been informed that its Pacer Cardioverter Defibrillator (PCD)(TM) device will be reviewed at the U.S. Food and Drug Administration's circulatory systems panel meeting Feb. 3, 1992.
 FDA panels, comprised of physicians and other specialists knowledgable about medical or technical issues related to drugs or devices under consideration, advise the agency as it processes applications for subsequent commercial approval.
 The PCD, which has been in clinical trials since 1989, is designed to offer staged therapy to treat tachyarrhythmia -- an abnormally fast heartbeat.
 Medtronic, Inc., headquartered in Minneapolis, is a leading developer and manufacturer of biomedical devices for improving cardiovascular and neurological health.
 -0- 1/08/92
 /CONTACT: Dale Beumer (Investor Relations), 612-574-3038 or Dick Reid (Public Relations) 612-574-3052, both of Medtronic/
 (MDT) CO: Medtronic, Inc. ST: Minnesota IN: MTC SU:


DS -- MN005 -- 7605 01/08/92 08:57 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 1992
Words:165
Previous Article:UPJOHN ACQUIRES GERMAN COMPANY
Next Article:DOSKOCIL ANNOUNCES INITIAL DISTRIBUTION OF STOCK; IMPROVED FOURTH QUARTER EARNINGS
Topics:


Related Articles
MEDTRONIC INFORMS PCD CLINICAL INVESTIGATORS OF ANIMAL STUDY OBSERVATIONS
MEDTRONIC REPORTS REGULATORY ACTION ON TACHYARRHTHMIA DEVICE
EPITOPE'S ORASURE PREMARKET APPROVAL APPLICATION SCHEDULED FOR REVIEW BY FDA ADVISORY PANEL
FDA ADVISORY PANEL RECOMMENDS APPROVAL OF LESS-INVASIVE LEADS FOR PCD SYSTEM
FDA APPROVES U.S. CLINICAL EVALUATION OF NEW MEDTRONIC DEVICE FOR HEARTS THAT BEAT TOO FAST
MEDTRONIC ANNOUNCES FIRST U.S. IMPLANT OF NEW, SIMPLER DEVICE FOR HEARTS THAT BEAT TOO FAST
MEDTRONIC ANNOUNCES FIRST U.S. IMPLANT OF NEW, SIMPLER DEVICE FOR HEARTS THAT BEAT TOO FAST
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC RF CARDIAC ABLATION SYSTEM AT MEETING DECEMBER 5
FDA ADVISORY PANEL RECOMMENDS APPROVAL OF MEDTRONIC RF CARDIAC ABLATION SYSTEM

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters